Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), Intellia Therapeutics (NTLA) and Immunic (IMUX)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ascendis Pharma (ASND – Research Report), Intellia Therapeutics (NTLA – Research Report) and Immunic (IMUX – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ascendis Pharma (ASND)
In a report released today, Paul Choi from Goldman Sachs maintained a Buy rating on Ascendis Pharma, with a price target of $255.00. The company’s shares closed last Friday at $233.50.
According to TipRanks.com, Choi is a 4-star analyst with an average return of
Ascendis Pharma has an analyst consensus of Strong Buy, with a price target consensus of $287.42, a 25.0% upside from current levels. In a report issued on February 17, Morgan Stanley also maintained a Buy rating on the stock with a $256.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Intellia Therapeutics (NTLA)
Truist Financial analyst Joon Lee maintained a Buy rating on Intellia Therapeutics today. The company’s shares closed last Friday at $13.78.
According to TipRanks.com, Lee is a top 100 analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Intellia Therapeutics with a $17.10 average price target, representing a 23.6% upside. In a report issued on February 26, TD Cowen also maintained a Buy rating on the stock.
Immunic (IMUX)
In a report released today, Boobalan Pachaiyappan from Roth MKM reiterated a Buy rating on Immunic, with a price target of $3.00. The company’s shares closed last Friday at $1.02, close to its 52-week low of $0.92.
According to TipRanks.com, Pachaiyappan is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Immunic with a $3.67 average price target, representing a 287.3% upside. In a report issued on February 23, William Blair also maintained a Buy rating on the stock.
